POLG and Hepatic failure: It has been shown that VPA should not to be used to treat patients with mitochondrial disease, particularly because patients with POLG mutations are at increased risk for VPA-induced liver failure (Ferrari et al., 2005; Gordon, 2006; Uusimaa et al., 2008; Stewart et al., 2009).